$3.03 Million in Sales Expected for Advaxis, Inc. (ADXS) This Quarter

Brokerages predict that Advaxis, Inc. (NASDAQ:ADXS) will report sales of $3.03 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Advaxis’ earnings, with the lowest sales estimate coming in at $3.00 million and the highest estimate coming in at $3.05 million. Advaxis reported sales of $3.79 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 20.1%. The business is scheduled to issue its next earnings report on Friday, March 9th.

According to Zacks, analysts expect that Advaxis will report full year sales of $3.03 million for the current fiscal year, with estimates ranging from $12.21 million to $13.00 million. For the next fiscal year, analysts anticipate that the firm will report sales of $12.68 million per share, with estimates ranging from $12.27 million to $13.10 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Advaxis.

Advaxis (NASDAQ:ADXS) last released its quarterly earnings data on Wednesday, December 20th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.02). The firm had revenue of $1.76 million during the quarter, compared to analyst estimates of $3.05 million. Advaxis had a negative net margin of 776.63% and a negative return on equity of 114.00%.

Several research firms have recently weighed in on ADXS. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Advaxis in a research note on Wednesday, November 8th. Cantor Fitzgerald set a $19.00 price objective on Advaxis and gave the company a “buy” rating in a research note on Thursday, December 28th. Finally, ValuEngine raised Advaxis from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.

Advaxis (NASDAQ:ADXS) opened at $2.63 on Friday. The firm has a market capitalization of $105.20, a PE ratio of -1.14 and a beta of 0.70. Advaxis has a 52 week low of $2.43 and a 52 week high of $10.06.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ADXS. Voya Investment Management LLC lifted its stake in shares of Advaxis by 20.3% in the 2nd quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 2,975 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Advaxis by 18.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 26,000 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 4,000 shares during the period. Stonebridge Capital Management Inc. raised its holdings in shares of Advaxis by 88.7% during the 3rd quarter. Stonebridge Capital Management Inc. now owns 42,650 shares of the biotechnology company’s stock valued at $179,000 after buying an additional 20,045 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Advaxis by 39.9% during the 4th quarter. Wells Fargo & Company MN now owns 66,206 shares of the biotechnology company’s stock valued at $187,000 after buying an additional 18,892 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Advaxis by 10.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,431 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 2,969 shares during the period. 42.60% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/02/11/3-03-million-in-sales-expected-for-advaxis-inc-adxs-this-quarter.html.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Get a free copy of the Zacks research report on Advaxis (ADXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply